Form 4: Arrowhead Pharmaceuticals CFO Sells 40,000 Shares

Kenneth Allen Myszkowski, CFO of Arrowhead Pharmaceuticals, sold 40,000 shares of common stock on March 6, 2024, at an average price of $35.19.

Summary

• Kenneth Allen Myszkowski, the Chief Financial Officer of Arrowhead Pharmaceuticals, sold 40,000 shares of the company's common stock on March 6, 2024.
• The sale was executed at a weighted average price of $35.19 per share.
• The prices for individual transactions ranged from $35.00 to $35.53.
• Following the reported transaction, Myszkowski still beneficially owns 400,600 shares, including shares underlying Restricted Stock Units subject to vesting conditions.

Sentiment

Score: 5

Explanation: Neutral sentiment as it's a standard disclosure of an insider transaction. The sale itself doesn't necessarily indicate a positive or negative outlook.

Industry Context

This is a routine disclosure of an insider transaction. It's common for executives to periodically sell shares for personal financial management.

Stakeholder Impact

• The sale could have a minor negative impact on shareholder sentiment, but is unlikely to have a significant long-term effect.

Key Dates